DNJ-20
DNJ-20 is an α-glucosidase inhibitor (IC50: 55.3 μg/mL) . DNJ-20 has broad-spectrum anti-SARS-CoV-2 activity. DNJ-20 inhibits the correct processing of viral glycoproteins by interfering with the endoplasmic reticulum-associated glycoprotein folding process (ERQC), thereby blocking the formation and infection of viral particles. DNJ-20 has IC50 values up to 1.49 uM against several SARS-CoV-2 variants, as well as HCoV-229E and HCoV-0C43。DNJ-20 can be used for pan-coronavirus research[1].
Product Specifications
CAS Number
3081926-49-7
UNSPSC
12352005
Target
Glycosidase; SARS-CoV
Related Pathways
Anti-infection; Metabolic Enzyme/Protease
Field of Research
Infection; Inflammation/Immunology
Smiles
O=C1C=C(C2=CC=C(O)C(O)=C2)OC3=C1C(OCCCCCCCCCCN4[C@H](CO)[C@@H](O)[C@H](O)[C@@H](O)C4)=CC(O)=C3
Molecular Formula
C31H41NO10
Molecular Weight
587.66
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Glucosidase
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
IgA Secretory Component (SC05), CF568 conjugate, 0.1mg/mL
CD44 Standard (156-3C11), CF647 conjugate, 0.1mg/mL
